NorthWest Biotherapeutics Inc (NWBO)

[jimmy667]

Check your figures. Fisrt approval should value NWBO in the $20-30 billion range. It should be a 10x bagger before approval. Been in stocks trading less than $200 million market cap and made the mistake of selling at only a 10x 1000% gain as they were on the way to 40x. One of those stocks Arrowhead yesterday licenced one of there minor early stage drugs in a $1 billion deal. Market cap $7 billion and just have one minor drug approved. ARWR moved from $1 -2 sp range to $17-20 in less than a year where I sold then in 18 months moved to $70+ . That is just one example. NWBO can and should move like that after they move to a major exchange. NWBO if successful should be valued $20-50 billion. This is especially true as they are managing and reduceing execution risks parallel with the regulatory advances. NWBO is so confident that they are working on vertical integration before approval.
NWBO much larger near term potential than ARWR in a more narrow indication but they are working on vertical integration in large scale manufacturing.
I see NWBO approaching multiple parabolic moves as ARWR did over the past 5 years. AVXL is another example. 14 cents to $30 now $18 in just a few years.
When NWBO is a 10x or 20x bagger from here it will just be the start of the run to a 50x-100x bagger. Time and uplist will get NWBO very valuable. Make no mistake NWBO true value right now before TLD should be $3-4 billion. With great date 10x that. Commercial success in time might gain another 5x-10x in market cap plus dividends potentially.
The data is a lock. The results of the trial are a near lock. When the Sawston facility is certified manufacturing will be a lock. Demand for the drug will be a lock. Expansion trials into other solid tumors will come near certainly so future growth prospects are a lock. There maybe only 5 biotech stocks with this amount of potential and two are on OTC. None other than NWBO is a near lock to be a success. Eighteen months a modest number is shares and uplist nets $million in capital gains for the patient investor.